Avoro Capital Advisors LLC Acquires Significant Stake in Ocular Therapeutix Inc
OCUL Stock | USD 7.89 0.95 13.69% |
About 54% of Ocular Therapeutix's institutional investors are presently thinking to get in. The analysis of overall sentiment of trading Ocular Therapeutix stock suggests that some investors are interested at this time. Ocular Therapeutix's investing sentiment shows overall attitude of investors towards Ocular Therapeutix.
Overview of the Recent Transaction On September 30, 2024, Avoro Capital Advisors LLC , a prominent investment firm, expanded its portfolio by
Read at gurufocus.com
![]() |
Ocular Therapeutix Fundamental Analysis
We analyze Ocular Therapeutix's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ocular Therapeutix using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ocular Therapeutix based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Asset
Current Asset Comparative Analysis
Ocular Therapeutix is currently under evaluation in current asset category among its peers. Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Ocular Therapeutix Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Ocular Therapeutix stock to make a market-neutral strategy. Peer analysis of Ocular Therapeutix could also be used in its relative valuation, which is a method of valuing Ocular Therapeutix by comparing valuation metrics with similar companies.
Peers
Ocular Therapeutix Related Equities
SPRO | Spero Therapeutics | 245.59 | ||||
CTMX | CytomX Therapeutics | 12.68 | ||||
HOOK | Hookipa Pharma | 5.30 | ||||
TERN | Terns Pharmaceuticals | 1.66 | ||||
AMLX | Amylyx Pharmaceuticals | 1.48 | ||||
MREO | Mereo BioPharma | 0.46 | ||||
INZY | Inozyme Pharma | 0.25 | ||||
DAWN | Day One | 0.16 | ||||
ABOS | Acumen Pharmaceuticals | 0.97 | ||||
ASMB | Assembly Biosciences | 2.41 | ||||
XFOR | X4 Pharmaceuticals | 4.13 | ||||
PDSB | PDS Biotechnology | 4.20 |
Check out Ocular Therapeutix Hype Analysis, Ocular Therapeutix Correlation and Ocular Therapeutix Performance. For more information on how to buy Ocular Stock please use our How to buy in Ocular Stock guide.You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ocular Therapeutix. If investors know Ocular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ocular Therapeutix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Ocular Therapeutix is measured differently than its book value, which is the value of Ocular that is recorded on the company's balance sheet. Investors also form their own opinion of Ocular Therapeutix's value that differs from its market value or its book value, called intrinsic value, which is Ocular Therapeutix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ocular Therapeutix's market value can be influenced by many factors that don't directly affect Ocular Therapeutix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ocular Therapeutix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ocular Therapeutix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ocular Therapeutix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.